AZTREONAM FOR INHALATION SOLUTION (AZLI) TREATMENT IN CHILDREN WITH CYSTIC FIBROSIS (CF) AND CHRONIC PSEUDOMONAS AERUGINOSA (PA) INFECTION

被引：0

作者：

Accurso, F. J. ^{[1
]}

Fayon, M. ^{[2
]}

Sermet, I. ^{[3
]}

Lewis, S. ^{[4
]}

Bresnik, M. ^{[5
]}

Oermann, C. M. ^{[6
]}

机构：

[1] UCD Childrens Hosp Colorado, Dept Pediat, Aurora, CO USA

[2] CHU Bordeaux, CIC 0005, Bordeaux, France

[3] Hop Necker Enfants Malad, CHU Paris, Paris, France

[4] Gilead Sci Inc, Seattle, WA USA

[5] Gilead Sci Inc, Foster City, CA 94404 USA

[6] Baylor Coll Med, Houston, TX 77030 USA

来源：

PEDIATRIC PULMONOLOGY | 2013年 / 48卷

关键词：

D O I：

暂无

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

引用

页码：343 / 343

页数：1

共 50 条

[1] AZTREONAM FOR INHALATION SOLUTION (AZLI) FOR ERADICATION OF NEW ONSET PSEUDOMONAS AERUGINOSA (PA) INFECTION IN CHILDREN WITH CYSTIC FIBROSIS (CF): INITIAL RESULTS FROM A PHASE 2 STUDY
Tiddens, H.
DeBoeck, C.
Clancy, J. P.
Fayon, M.
Arets, B.
Bresnik, M.
Derchak, A.
Oermann, C. M.
[J]. PEDIATRIC PULMONOLOGY, 2013, 48 : 293 - 293
[2] Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis
Assael, Baroukh Maurice
[J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2011, 9 (11) : 967 - 973
[3] ANTIBIOTIC SUSCEPTIBILITY IN PSEUDOMONAS AERUGINOSA (PA) ISOLATES FOLLOWING REPEATED EXPOSURE TO AZTREONAM FOR INHALATION SOLUTION (AZLI) IN PATIENTS WITH CYSTIC FIBROSIS
Oermann, C. M.
McCoy, K. S.
Retsch-Bogart, G. Z.
Gibson, R.
McKevitt, M.
Montgomery, B.
[J]. PEDIATRIC PULMONOLOGY, 2009, : 309 - 309
[4] AZTREONAM FOR INHALATION SOLUTION (AZLI) AND TOBRAMYCIN INHALATION SOLUTION (TIS) CONTINUOUS ALTERNATING THERAPY (CAT) FOR CYSTIC FIBROSIS (CF) PATIENTS WITH CHRONIC PSEUDOMONAS AERUGINOSA (PA) INFECTION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Flume, P. A.
Clancy, J. P.
Retsch-Bogart, G. Z.
Tullis, E.
Bresnik, M.
Derchak, P. A.
Lewis, S. A.
Ramsey, B. W.
[J]. PEDIATRIC PULMONOLOGY, 2015, 50 : 352 - 353
[5] EFFECTS OF CONTINUOUS AZTREONAM FOR INHALATION SOLUTION (AZLI) USE ON PATHOGENS AND ANTIBIOTIC SUSCEPTIBILITY IN CYSTIC FIBROSIS (CF) PATIENTS WITH CHRONIC BURKHOLDERIA SPECIES INFECTION
Tullis, E.
LiPuma, J. J.
Retsch-Bogart, G.
Bresnik, M.
Henig, N.
McKevitt, M.
Lewis, S.
Burns, J. L.
[J]. PEDIATRIC PULMONOLOGY, 2011, : 305 - 305
[6] Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa
Wainwright, C. E.
Quittner, A. L.
Geller, D. E.
Nakamura, C.
Wooldridge, J. L.
Gibson, R. L.
Lewis, S.
Montgomery, A. B.
[J]. JOURNAL OF CYSTIC FIBROSIS, 2011, 10 (04) : 234 - 242
[7] LUNG FUNCTION IMPROVEMENT WITH AZTREONAM FOR INHALATION SOLUTION (AZLI) IN THE SINGLE-ARM EXTENSION OF A RANDOMIZED TRIAL OF INHALED ANTIPSEUDOMONAL ANTIBIOTICS IN PATIENTS WITH CYSTIC FIBROSIS (CF) AND PSEUDOMONAS AERUGINOSA INFECTION
Assael, B. M.
Chiron, R.
Fischer, R.
Bresnik, M.
Lewis, S.
Pressler, T.
Oermann, C. M.
[J]. PEDIATRIC PULMONOLOGY, 2011, : 312 - 312
[8] AZTREONAM FOR INHALATION SOLUTION (AZLI) VS. TOBRAMYCIN INHALATION SOLUTION (TIS), A 6-MONTH COMPARATIVE TRIAL IN CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
Oermann, C. M.
Assael, B.
Nakamura, C.
Boas, S. R.
Bresnik, M.
Montgomery, A. B.
Pressler, T.
[J]. PEDIATRIC PULMONOLOGY, 2010, : 327 - 327
[9] Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis
Stockmann, Chris
Hillyard, Brad
Ampofo, Krow
Spigarelli, Michael G.
Sherwin, Catherine M. T.
[J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (01) : 13 - 22
[10] EFFECTS OF CHRONIC INTERMITTENT AZTREONAM FOR INHALATION SOLUTION (AZLI) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PERSONS WITH CYSTIC FIBROSIS (CF) AND P. AERUGINOSA
Quittner, A. L.
Henig, N. R.
Lewis, S.
Derchak, P. A.
McCoy, K. S.
Oermann, C. M.
Retsch-Bogart, G. Z.
[J]. PEDIATRIC PULMONOLOGY, 2011, : 299 - 299

← 1 2 3 4 5 →